Elan sells back Frova rights
Executive Summary
Vernalis will seek new commercialization partner for migraine therapy Frova (frovatriptan) after buying back U.S. rights from Elan in $55 mil. deal. London-based Vernalis plans 2005 U.S. filing for new indication in menstrually-associated migraine. Phase III safety study is underway; pivotal efficacy trial slated to begin in second quarter. Elan's 2003 revenue for Frova was $37.5 mil...